Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

This marks the first and only FDA-approved medicine for low-grade serous ovarian cancer (LGSOC) that tests positive for a gene change known as the KRAS mutation. The treatment includes two drugs ...

Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

The FDA recently approved a new tool in the fight against cervical cancer: the first-ever test that can be done at home. Dr. Ashlesha Patel, associate chair of obstetrics and gynecology at Cook County ...

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ...

Verastem Oncology said the Food and Drug Administration approved the combination of Avmapki capsules and Fakzynja tablets for certain ovarian-cancer patients. The company said Thursday it expects ...